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Nutritional ketosis has been proven effective for seizure disorders and other
neurological disorders. The focus of this study was to determine the effects of ketone
supplementation on anxiety-related behavior in Sprague-Dawley (SPD) and Wistar
Albino Glaxo/Rijswijk (WAG/Rij) rats. We tested exogenous ketone supplements added
to food and fed chronically for 83 days in SPD rats and administered sub-chronically for
7 days in both rat models by daily intragastric gavage bolus followed by assessment
of anxiety measures on elevated plus maze (EPM). The groups included standard
diet (SD) or SD + ketone supplementation. Low-dose ketone ester (LKE; 1,3-
butanediol-acetoacetate diester, ∼10 g/kg/day, LKE), high dose ketone ester (HKE;
∼25 g/kg/day, HKE), beta-hydroxybutyrate-mineral salt (βHB-S; ∼25 g/kg/day, KS)
and βHB-S + medium chain triglyceride (MCT; ∼25 g/kg/day, KSMCT) were used as
ketone supplementation for chronic administration. To extend our results, exogenous
ketone supplements were also tested sub-chronically on SPD rats (KE, KS and KSMCT;
5 g/kg/day) and on WAG/Rij rats (KE, KS and KSMCT; 2.5 g/kg/day). At the end of
treatments behavioral data collection was conducted manually by a blinded observer
and with a video-tracking system, after which blood βHB and glucose levels were
measured. Ketone supplementation reduced anxiety on EPM as measured by less
entries to closed arms (sub-chronic KE and KS: SPD rats and KSMCT: WAG/Rij rats),
more time spent in open arms (sub-chronic KE: SPD and KSMCT: WAG/Rij rats; chronic
KSMCT: SPD rats), more distance traveled in open arms (chronic KS and KSMCT:
SPD rats) and by delayed latency to entrance to closed arms (chronic KSMCT: SPD
rats), when compared to control. Our data indicates that chronic and sub-chronic
ketone supplementation not only elevated blood βHB levels in both animal models,
but reduced anxiety-related behavior. We conclude that ketone supplementation may
represent a promising anxiolytic strategy through a novel means of inducing nutritional
ketosis.
Keywords: anxiety, exogenous ketone supplements, ketones, elevated plus maze, animal models
Abbreviations: 5-HT, Serotonin; AD, Alzheimer’s disease; βHB, beta-hydroxybutyrate; CNS, central nervous system;
EPM, elevated plus maze; GLUT1 DS, Glucose transporter type-1 deficiency syndrome; HKE, high-dose ketone ester; KD,
ketogenic diet; LKE, low-dose ketone ester; MCT, medium chain triglyceride; SD, standard diet; SPD rats, Sprague-Dawley
rats; WAG/Rij rats, Wistar Albino Glaxo/Rijswijk rats.
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INTRODUCTION
Anxiety disorders, such as generalized anxiety disorder, phobia
and panic disorder, are the most prevalent type of mental
disorders (Li, 2012). Anxiety can be associated with psychiatric
morbidity, disability, increased healthcare burden and mortality
in the general population (Teri et al., 1999). These symptoms
can cause significant distress interfering with a person’s quality
of life, while they commonly occur along with other mental
or physical illnesses, which may mask anxiety symptoms
or aggravate them. Some symptoms, like fear and worry,
occur in all anxiety disorders including generalized anxiety
disorders, panic disorder and social anxiety disorder (Stahl,
2003; Mula, 2013). Our knowledge relating to exact cause and
pathomechanism(s) of anxiety disorders is far from complete;
however, it is known that the amygdala is determinant in the
experience of fear and anxiety by mediating the autonomic and
endocrine responses through the output to the hypothalamus,
and avoidance behavior through the output to the periaqueductal
gray matter (Stahl, 2003; Engin and Treit, 2008; Li, 2012;
Mula, 2013). Previous studies also show that serotonergic,
glutamatergic as well as GABAergic system have a role in the
regulation of anxiety (Nagy et al., 1979; Kakui et al., 2009; Li,
2012; Dias et al., 2013). Anxiety and depression are common
problems affecting people with epilepsy and Alzheimer’s disease
(AD), and can exacerbate symptoms of Glucose transporter
type-1 deficiency syndrome (GLUT1 DS). Comorbidity between
anxiety, depression and AD has been recognized (Teri et al.,
1999; Hamid et al., 2011; Mula, 2013), and anxiety plays a
key role in suicidality among patients with depression (Placidi
et al., 2000). Interestingly, the same brain regions involved
in a significant proportion of patients with focal epilepsy,
such as the amygdala and the hippocampus, also play a key
role in the neurobiology of anxiety (Li, 2012; Dias et al.,
2013).
Anecdotal reports suggest that nutritional ketosis can
promote a reduction in anxiety, although there is currently
no convincing evidence to indicate that elevated ketone
levels would reduce anxiety in humans (Ehrenreich, 2006).
The elevation of ketones such as beta-hydroxybutyrate (βHB)
and acetoacetate (AcAc) associated with nutritional ketosis
causes a fundamental shift in metabolic physiology and brain
neuropharmacology that is associated with preservation of
brain homeostasis (Bough and Rho, 2007; Yudkoff et al.,
2007; D’Agostino et al., 2013). Ketosis can be achieved by
prolonged fasting (Owen et al., 1967) or by strict adherence to
a ketogenic diet (KD), which is a metabolic-based therapy, a
high-fat (70%–85% kcal) and low carbohydrate (3%–5%) diet
(Kwiterovich et al., 2003; De Giorgis and Veggiotti, 2013).
Maintaining long-term ketosis has proven to be beneficial in
epileptic patients by decreasing the frequency and severity of
seizures (Kossoff et al., 2011). Nutritional ketosis has also
confirmed beneficial effects in animal models and human
patients with AD, GLUT1 DS and cancer (Poff et al., 2013,
2014; Veggiotti and De Giorgis, 2014; Newport et al., 2015).
GLUT1 DS results from impaired glucose transport into the
brain (Klepper and Voit, 2002), however, ketones use another
transporter to enter the central nervous system (CNS) providing
an alternative source of fuel. Therefore, nutritional ketosis is
used as a treatment option in GLUT1 patients (De Giorgis
and Veggiotti, 2013) effectively correcting the impaired brain
energy metabolism, reducing the frequency of the seizures
(Leen et al., 2010) and improving behavior in autism spectrum
disorder (Herbert and Buckley, 2013). Despite the proven and
emerging therapeutic applications of the KD, many patients
experience difficulties with compliance or experience a loss of
effectiveness over time; therefore, new therapeutic strategies are
needed.
The Wistar Albino Glaxo/Rijswijk (WAG/Rij) rat strain was
originally developed as an animal model of human absence
epilepsy, as the animals show spontaneous spike-wave discharges
in the EEG (Coenen and Van Luijtelaar, 2003). Nevertheless,
WAG/Rij rats are often used for investigation of different CNS
diseases, such as anxiety, similar to Sprague-Dawley (SPD) rats
by means of elevated plus maze (EPM; Sarkisova et al., 2003;
Kovács et al., 2006, 2012, 2015; Sarkisova and Kulikov, 2006;
Sarkisova and van Luijtelaar, 2011; Rebuli et al., 2015). EPM
is a widely used behavioral assay for rodents, and it has been
validated to assess the anxiety responses of rodents (Pellow
et al., 1985; Walf and Frye, 2007). This test relies upon rodents’
proclivity toward dark enclosed spaces (approach) and an
unconditioned fear of heights/open spaces (avoidance; Barnett,
1975; Walf and Frye, 2007). It is a widely-used animal model
and investigation method of anxiety that is primarily sensitive
to benzodiazepine-type anxiolytics (e.g., diazepam; Paslawski
et al., 1996). Anti-anxiety behavior (increased open arm time
and/or open arm entries) can be determined, which reflects
the rodent’s preference for protected areas (e.g., closed arms)
and their innate motivation to explore novel environments
(Walf and Frye, 2007). Consequently, EPM assay on SPD
and WAG/Rij rats is a suitable method for investigate the
effect of ketone supplementation-evoked changes on anxiety
level.
We hypothesized that ketone supplementation would
decrease measures of anxiety-related behavior assessed with
EPM behavioral assay in two rat strains. We have previously
characterized the effects of ketone supplementation on blood
ketone levels given via intragastric gavage (D’Agostino et al.,
2013; Kesl et al., 2015) in rats and via chronic feeding mice
(Poff et al., 2014). Ketone supplementation causes a rapid
and sustained increase in blood ketone level, which may
evoke anxiolytic effect by the increase of the GABAergic
effects (Yudkoff et al., 2007; Li, 2012) or through numerous
neuropharmacological pathways (Rho, 2015). To ensure that
our results were not strain dependent, we assessed the effects
of ketone supplementation on anxiety in SPD rats as well as
in WAG/Rij rats, which have reduced activity of GABAergic
system (Luhmann et al., 1995). Thus, the focus of this study
was to test and determine the effects of several forms of
ketone supplementation on anxiety-related behavior by using
EPM behavioral assay in two rat strains. Exogenous ketone
supplements were fed chronically to SPD rats and administered
sub-chronically (gavage bolus) to SPD rats and WAG/Rij rats
prior to assessment of anxiety measures.
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MATERIALS AND METHODS
Animals
Two months old male SPD (n = 87) and 8 months old
male WAG/Rij (n = 32) rats were used in the experiments.
The animals were housed at Department of Molecular
Pharmacology and Physiology (Hyperbaric Biomedical Research
Laboratory, Morsani College of Medicine, University of South
Florida, Tampa, FL, USA) and the Department of Zoology
(University of West Hungary, Savaria Campus, Szombathely,
Hungary). Animals were kept in groups of 2–4 under standard
laboratory conditions (12:12 h light-dark cycle, light was on
from 08:00 AM to 08:00 PM) in air-conditioned rooms at
22± 2◦C.
Animal treatment and measuring procedures were performed
in accordance with the University of South Florida Institutional
Animal Care and Use Committee (IACUC) guidelines (Protocol
#0006R) and with the local ethical rules in accordance with
the Hungarian Act of Animal Care and Experimentation (1998.
XXVIII. Section 243/1998) in conformity with the regulations for
animal experimentation in the European Communities Council
Directive of 24 November 1986 (86/609/EEC). All experiments
were approved by the University of South Florida IACUC
and all efforts were made to reduce the number of animals
used.
Synthesis and Formulation of Ketone
Precursors
Ketone ester (KE; 1,3-butanediol-acetoacetate diester) was
synthesized as previously described (D’Agostino et al., 2013).
Ketone salt (KS, which is Na+/K +–β-hydroxybutyrate mineral
salt) is a novel agent that was mixed into a 50% solution
supplying approximately 375 mg/g of pure βHB and 125 mg/g
of Na+/K+ in a 1:1 ratio. Both KE and KS were developed
and synthesized in collaboration with Savind Inc. Human food
grade medium chain triglyceride (MCT) oil (∼60% caprylic
triglyceride/40% capric triglyceride) was purchased from Now
Foods (Bloomingdale, IL, USA). KS was mixed with MCT in
a 1:1 ratio (KSMCT) at the University of South Florida (USF,
Tampa, FL, USA).
Ketone Supplementation
In order to determine the effect of different administration
forms, we tested chronic administration, when the ketone
supplementation was mixed into the regular rodent chow,
which the animals had access to all day for several weeks, and
sub-chronic administration when the ketone supplementation
was gavaged orally at a single time point daily for only
7 days.
Chronic Administration
A total of 48 male SPD rats were fed for 83 days with either
standard rodent chow (2018 Teklad Global 18% Protein Rodent
Diet (#2018), Harlan) standard diet (SD)/control; n = 9) or SD +
ketone supplementation. Four treatment animal groups included
low-dose KE (∼10 g/kg b.w./day, Low-dose ketone ester (LKE);
n = 10), high-dose KE (∼25 g/kg b.w./day, high dose ketone
ester (HKE); n = 10), KS (∼25 g/kg b.w./day, KS; n = 9) and
KSMCT (∼25 g/kg b.w./day, KSMCT; n = 10). Higher dose was
used for chronic administration, as the rats were consuming
food-integrated ketone supplementation throughout the day, not
at a single time point.
Sub-Chronic Oral Gavage
In order to familiarize the animals to the intragastric
gavage method, water was gavaged for 5 days before ketone
supplementation. Following the adaptation period to the
intragastric gavage method, 39 male SPD rats were fed with
standard diet, described in previous studies (Poff et al., 2013) and
gavaged daily with 5 g/kg b.w./day water (SD/control; n = 11)
or ketone supplements KE (n = 9), KS (n = 9), KSMCT (n = 10)
sub-chronically for 7 days.
In addition, following the adaptation period to the intragastric
gavage method, WAG/Rij male rats (n = 32) were fed with
SD and gavaged sub-chronically with ∼2.5 g/kg b.w./day water
(SD/control; n = 8), KE (n = 8), KS (n = 8) or KSMCT (n = 8)
for 7 days. For the sub-chronic gavage administration the gavage
dose was used that induced desired elevation of blood ketone
based on our previous studies (Kesl et al., 2016).
Anxiety Assay
EPM (Coulbourn Instruments) was used to assess anxiety-related
behavior of the rats after 83 days of chronic feeding or after
7 days of oral gavage. EPM experiments were carried out under
non-stress conditions (in dimly lit and quiet room) between
12.00 h and 14.00 h.
The rats were transferred in their home cage to the
experimental room 30 min prior to beginning the experiment.
Briefly, rats were placed in the intersection of the four arms
of the EPM, facing the open arm opposite to where the
experimenter was and their behavior was recorded for 5 min.
The amount of time spent and number of entries made on
the open arms, closed arms and the center zones were video
recorded. Latency to entry into the closed arms and the
distance traveled in each zones was also measured in chronically
treated SPD rats. Only those behaviors are discussed at each
experimental scenario where significant difference was found.
At the end of the 5 min test the rats were removed from
the maze and placed back into their home cage. The maze
was cleaned with 70% alcohol and later with tap water and
dried with paper towel between rats. The primary method
for data collection was a video-tracking system with computer
interface and video camera (SMART V3.0 PLATFORM, Panlab,
Harvard Apparatus, Holliston, MA, USA), to automatically
collect behavioral data in SPD rats. A blinded observer was
present in the testing room separated from the maze by a
curtain, and collected EPM data in both SPD and WAG/Rij
animals.
Blood Analyses and Weight Measurement
In the chronic feeding study, blood βHB and glucose levels were
measured 24 h before the 1st day of ketone treatments (baseline
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levels) and at 13th week after the EPM experiment. In the 7 day
oral gavage studies, blood βHB and glucose levels were measured
24 h before the 1st day of ketone treatments (baseline levels;
SPD and WAG/Rij rats), 24 h after the first gavage and 60 min
after gavage on the 7th day (SPD and WAG/Rij rats). Whole
blood samples (10 µL) were taken from the saphenous vein for
analysis of blood glucose (mg/dl) and βHB (mmol/l) levels with
the commercially available glucose and ketone (βHB)monitoring
system Precision XtraTM (Abbott Laboratories, Abbott Park,
IL, USA).
The body weight of all animals was recorded before the first
ketone treatment (before) and on the last day of the ketone
treatment (after).
Statistics
All data are presented as the mean ± standard error of the mean
(SEM). We compared the effects of ketone supplementations
on anxiety-related behavior as well as on blood βHB and
glucose levels to control or/and baseline levels. Data analysis
was performed using GraphPad PRISM version 6.0a. Results
were considered significant when p < 0.05. Significance was
determined by one-way analysis of variance (ANOVA) with
Fisher’s LSD test for the behavioral data. Blood ketone, blood
glucose and body weight change were compared using a two-way
ANOVA with Tukey’s multiple comparisons test.
RESULTS
Ketone Supplementation Reduced Anxiety
on Elevated Plus Maze
More Time Spent in Open Arms with Ketone
Supplements
After chronic feeding of ketone supplementation in SPD rats the
time spent in the open arms was significantly more in KSMCT
group (p = 0.0094), while time spent in the closed arms was
significantly less in LKE, KS and KSMCT groups (p = 0.0389,
0.0077 and 0.0019, respectively), compared to the control (SD)
in SPD rats. Time spent in the center was significantly more in
KS group (p = 0.0239; Figure 1A).
FIGURE 1 | Response of Sprague-Dawley (SPD) rats to chronic feeding of exogenous ketone supplementation. (A) Rats consuming KSMCT supplements
spent more time in open arms (open), Low-dose ketone ester (LKE), KS and KSMCT groups spent less time in closed arms (closed), showing reduced anxiety
compared to control (SD) group; (B) Rats consuming ketone supplements traveled more distance in open arms (KS and KSMCT) and less in closed arms (LKE, KS
and KSMCT), showing reduced anxiety compared to control group; (C) Rats consuming KSMCT entered the closed arms later, showing reduced anxiety compared
to control group; (D) Rats consuming high dose ketone ester (HKE), KS and KSMCT showed elevated blood ketone levels after 13 weeks (after) compared to control
group; (E) Blood glucose levels did not change significantly were lower in HKE and KSMCT groups compared to control after 13 weeks; and (F) body weight was
lower in HKE group after 13 weeks compared to control. Abbreviations: SD, standard rodent chow + water (∼25 g/kg b.w. water/day); LKE, SD + LKE
(1,3-butanediol-acetoacetate diester, ∼10 g/kg b.w./day); HKE, SD + HKE (∼25 g/kg b.w./day); KS, SD + beta-hydroxybutyrate-mineral salt (βHB-S; ∼25 g/kg
b.w./day); KSMCT, SD + βHB-S+medium chain triglyceride (MCT; ∼25 g/kg b.w./day); (∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001; ∗∗∗∗p < 0.0001).
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FIGURE 2 | Response of SPD rats to 7 days oral administration (gavage) of exogenous ketone supplementation. (A) More time spent in open arms (open)
by KE group and less time spent in center by KE, KS and KSMCT groups were detected compared to control; (B) Less entries in closed arms (closed) by KE and KS
groups; (C) Blood βHB levels were higher in KE group after 24 h and in KS and KSMCT groups after 7 days, compared to control; (D) Blood glucose levels were
lower in KE group after 24 h and in KSMCT group compared to baseline, control and 24 h; (E) Body weight was lower in KE and KS groups compared to control after
7 days. Abbreviations: SD, standard rodent chow + water (∼5 g/kg b.w. water/day); KE, SD + ketone ester (1,3-butanediol-acetoacetate diester, ∼5 g/kg b.w./day);
KS, SD + beta-hydroxybutyrate-mineral salt (βHB-S; ∼5 g/kg b.w./day); KSMCT, SD + βHB-S + MCT (∼5 g/kg b.w./day); (∗p < 0.05; ∗∗∗p < 0.001; ∗∗∗∗p < 0.0001).
After 7 days of gavage administration in SPD rats, the time
spent in the open arms increased in the KE group (p = 0.0281),
whereas time spent in the center decreased in KE, KS and
KSMCT groups (p = 0.0005, <0.0001 and 0.023, respectively;
Figure 2A). InWAG/Rij rats the KSMCT treated rats spent more
time in the open arms (p = 0.0018) and less time in the closed
arms (p = 0.0003), whereas KE treated rats spent more time in
the center (p = 0.0027), compared to the control (SD) group
(Figure 3A).
Less Entries to Closed Arms with Ketone
Supplements
Entries to the closed arms were less frequent with KE and
KS treatment (p = 0.0436, 0.0234, respectively) in SPD and
with KSMCT treatment (p = 0.0014) in WAG/Rij rat models,
respectively, after 7 days of administration (Figures 2B, 3B). SPD
rats also entered fewer times to the center when treated with
KS (Figure 2A; p = 0.0193), compared to control (SD) animals.
Conversely, WAG/Rij rats made less entries to open arms in KE
treated group (p = 0.0318).
More Distance Traveled in Open Arms, Less in
Closed Arms and Delayed Latency of Entrance to
Closed Arms with Ketone Supplements
After chronic feeding in SPD rats, the distance traveled in
the open arms was significantly greater in KS and KSMCT
groups (p = 0.036 and 0.0165), and distance traveled in
the closed arms was significantly less in LKE, KS and
KSMCT groups (p = 0.0252, 0.00041 and 0.0032), compared
to the control (SD). Distance traveled in the center was
more in KS and KSMCT groups (p = 0.0206 and 0.0482;
Figure 1B).
The latency to first entrance of closed arms was significantly
greater in KSMCT group after chronic feeding (p = 0.0038;
Figure 1C).
Elevation of Blood βHB Levels with Ketone
Supplements
After 83 days of chronic feeding in SPD rats, blood βHB
levels remained significantly elevated in HKE, KS and KSMCT
groups, compared to control (p = 0.0004, <0.0001, 0.0014;
Figure 1D) while it decreased in SD compared to baseline
(p = 0.0307).
Blood βHB levels were elevated in SPD rats after 24 h of a
single gavage in KE group (Figure 2C; p = 0.0325), compared to
control.
In SPD rats βHB was elevated in KSMCT groups at
7 days compared to their level at 24 h and baseline
(p < 0.0001; Figure 2C). Blood βHB was also elevated in
KS and KSMCT treatment groups compared to control group
(p = 0.0194, <0.0001; Figure 2C). After 7 days of gavage, blood
βHBwas elevated in KE, KS and KSMCT groups inWAG/Rij rats
(p< 0.0001) compared to baseline, 24 h and control (Figure 3C).
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FIGURE 3 | Response of Wistar Albino Glaxo/Rijswijk (WAG/Rij) rats to 7 days oral administration of exogenous ketone supplementation. (A) More
time spent in open arms (open) and less time spent in closed arms (closed) by KSMCT group were demonstrated compared to control; (B) Less entries in closed
arms by KSMCT group and in open arms by KE group; (C) Blood βHB levels were higher in all treatment groups (KE, KS and KSMCT) after 7 days, compared to
baseline, 24h and control. (D) Blood glucose levels decreased after 24 h in KE group compared to control and baseline, but increased after 7 days compared to 24 h
in KE and KSMCT group; (E) Body weight did not change significantly in either groups. Abbreviations: SD, standard rodent chow + water (∼2.5 g/kg b.w.
water/day); KE, SD + ketone ester (1,3-butanediol-acetoacetate diester, ∼2.5 g/kg b.w./day); KS, SD + beta-hydroxybutyrate-mineral salt (βHB-S; ∼2.5 g/kg
b.w./day); KSMCT, SD + beta-hydroxybutyrate-mineral salt (BHB-S) + MCT (KSMCT; ∼2.5 g/kg b.w./day); (∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001; ∗∗∗∗p < 0.0001).
Ketone Supplementation and Blood
Glucose Levels
After 13 weeks of chronic feeding in SPD rats blood glucose did
not change significantly in any groups (Figure 1E).
However, in SPD rats, after sub-chronic ketone treatments,
blood glucose levels were lower at 24 h in KE group compared to
control (p< 0.0001; Figure 2D). After 7 days of oral gavage blood
glucose was lower in KSMCT compared to control, to baseline
and to the level at 24 h in SPD rats (p< 0.0001; Figure 2D).
In WAG/Rij rats the KE group had lower glucose levels after
24 h, compared to baseline levels (p = 0.0064), however after
7 days their level were elevated again, compared to the level at
24 h (p = 0.0006; Figure 3D). Moreover, glucose levels were
also elevated after 7 days compared to 24 h in KSMCT group
(Figure 3D).
Differences in Changes of Blood Ketone
and Glucose Levels Between the Two
Animal Models
There was significant difference in βHB levels between the
two animal models in KE and KSMCT groups at 7 days only
(Figure 4A). The glucose levels were different between the two
animal models in each treatment groups at each time points,
except in KSMCT group at 7 days (Figure 4B).
Body Weight Changes during Ketone
Supplementation
After chronic feeding, the body weight of SPD rats was lower
in HKE group compared to the control (p = 0.0366). The body
weight increased in SD and KSMCT groups, compared to their
baseline (p = 0.0015, 0.0012; Figure 1F).
After 7 days of treatment the body weight of SPD rats
increased in SD group, compared to its baseline (p = 0.0297).
The body weight was lower in KE and KS treatment groups
after 7 days, compared to control (p = 0.0005, <0.0001;
Figure 2E). In WAG/Rij rats the body weight did not change
significantly in either group during the treatment period
(Figure 3E).
DISCUSSION
The current study demonstrated the anxiolytic effect of chronic
(13 weeks) and sub-chronic (7 days) administration of several
forms of ketone supplementation in both SPD andWAG/Rij rats.
Anxiolytic effect was assessed by means of EPM andmeasured by
less entries and time spent in closed arms, more entries and time
spent in open arms, more distance traveled in open arms, and
delayed latency to entrance into closed arms.
Ketones are produced naturally in the liver only under
certain physiological conditions associated with the suppression
of the hormone insulin: starvation, fasting, calorie restriction,
prolonged exercise, or during the consumption of high fat,
low carbohydrate KD. The restrictive nature of these states
has limited the clinical applicability of therapeutic ketosis due
to practical considerations. In an effort to circumvent this
dilemma, researchers have recently developed a number of
exogenous ketogenic supplements, ketogenic precursors that are
metabolized to produce a dose-dependent elevation of βHB and
AcAc in the blood (Veech, 2004; Clarke et al., 2012; Kesl et al.,
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FIGURE 4 | Blood βHB and glucose levels compared between the two
animal models. (A) Blood βHB levels were higher at 7 days in WAG/Rij rats
after KE and KSMCT treatment. (B) Blood glucose levels were significantly
lower in WAG/Rij rats, except in KSMCT group at 7 days. (∗∗p < 0.01;
∗∗∗p < 0.001; ∗∗∗∗p < 0.0001).
2016). Induction of hyperketonemia produces acute and chronic
changes in metabolic physiology and neuropharmacological
pathways that provide therapeutic effects in varied disease
states. The ketone supplements tested in this study allowed
for a rapid and controlled induction of physiologic ketosis
without the need for fasting or severe dietary restrictions.
Previous studies have demonstrated the use of exogenous
ketones as a means to induce a dose-dependent hyperketonemia
(1–7 mM) in rats, mice, dogs, pigs and humans (Desrochers
et al., 1992, 1995; Ciraolo et al., 1995; Brunengraber, 1997;
Puchowicz et al., 2000; Clarke et al., 2012; Srivastava et al., 2012).
Exogenous ketogenic supplementationmimics themetabolic and
physiologic effects of the KD, including enhancingmitochondrial
biogenesis, anaplerosis, suppression of glycolysis and increasing
ATP and adenosine production, all thought to mediate the
therapeutic effects of KD in epilepsy (Veech, 2004; Srivastava
et al., 2012; Kesl et al., 2014; Poff et al., 2015). Since many of the
benefits of ketosis are mechanistically attributable to the ketone
bodies, it is possible that exogenous ketone supplementation
could mimic the therapeutic efficacy of the KD for certain
disorders, including anxiety disorders, or other disorders, such
as seizure disorders and AD that have a comorbidity of
anxiety.
The differences in blood βHB and glucose levels between the
two animal models both before and after the treatment highlight
the need to examine the response to ketone supplementation
in more rodent models with different pathologies. Both in
chronic and sub-chronic KE treatment resulted in lower
body weight in SPD animals, however, the body weight
did not change significantly during the treatment period in
WAG/Rij rats.
Previous studies have shown a clear anxiolytic effect in
the EPM when the antidepressant/antipanic drug phenelzine,
agonists and/or antagonists of different neurotransmitter
systems (e.g., GABAergic and glutamatergic system) were
given acutely to rats (Paslawski et al., 1996; Engin and Treit,
2008). Although, there is no compelling evidence that the KD
or elevated blood ketone levels would induce global changes
in GABA levels (Hartman et al., 2007), the exogenous ketone
supplementation tested in the present study similarly increased
the open arms exploration in the EPM and increased the latency
to enter the closed arms, showing anxiolytic effect.
In summary, LKE decreased time spent in closed arms
and reduced distance traveled in closed arms after chronic
treatment. Moreover, KE increased time spent in open arms,
decreased time spent in center and decreased number of
entries in closed arms after sub-chronic treatment in SPD
rats. KS was proven to be effective in reducing time spent
and distance traveled in closed arms and increase distance
traveled in open arms after chronic treatment. It also reduced
time spent and number of entries to center, while decreasing
number of entries in closed arms after sub-chronic treatment in
SPD rats. KSMCT effectively increased time spent and distance
traveled in open arms and decreased time spent and distance
traveled in closed arms, as well as delayed latency to first
entrance to closed arms after chronic treatment in SPD rats.
In WAG/Rij rats KSMCT successfully increased time spent in
open arms and decreased time spent and number of entries in
closed arms after sub-chronic treatment. Differences could be
observed between the effects of different ketone supplements
on anxiety. These results indicate that KS and KSMCT are the
most effective after chronic treatment, while KE and KS seem
to be the most effective after sub-chronic treatment in rats
without pathology (SPD). In rats with pathology (WAG/Rij)
KSMCT was the most effective treatment after sub-chronic
administration.
Previous studies showed that the percentage of open arm
entries linearly increase with age (Lynn and Brown, 2010) and
the aging-related changes in EPM behavior are strain-specific
(Ferguson and Gray, 2005), therefore the rats used in the
present study involved two strains and animals of different
age. In other studies, those rats that were pre-treated with
amphetamine exhibited increased anxiety-like behavior on the
EPM, which was successfully reversed by paroxetine, a selective
serotonin (5-HT) reuptake inhibitor (Tu et al., 2014). Those
results suggested that 5-HT levels in the ventral hippocampus
are critical for regulating anxiety behavior and that increasing
5-HT levels may be an effective strategy for reducing anxiety
(Tu et al., 2014). Therefore, we speculate that the ketone
supplements reduced anxiety-related behavior not solely by
elevating blood ketone levels, but may also effect the regulation
of 5-HT levels. In spite of that WAG/Rij rats show different
anxiety behavior compared to SPD rats (e.g., WAG/Rij rats spent
approximately equal times in the closed and open arms without
ketone supplementation: Figures 2A, 3A), sub-chronic ketone
supplementation was effective not only in SPD rats but also
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in WAG/Rij rats (Figures 2A,B, 3A,B). Thus, our results on
WAG/Rij rats strengthened the hypothesis on anxiolytic effect of
exogenous ketone supplementation found in SPD rats.
Previous studies demonstrated that 18% of Americans and
14% of Europeans may be affected by one or more anxiety
disorders (Kessler et al., 2005) that are associated with high
financial costs, increased risk of mortality and morbidity as
well as impaired workplace performance (Greenberg et al.,
1999; Albert et al., 2005). Ketone supplementation may be
a potential therapeutic intervention in treatment of anxiety
disorders (Yudkoff et al., 2007; Engin and Treit, 2008; Masino
et al., 2012; Lutas and Yellen, 2013), while very little is known
about the link between ketone application-evoked changes in
CNS and anxiety disorders. However, it has been demonstrated
that KD may: (i) decrease extracellular glutamate release/level
by means of inhibition of vesicular glutamate transporter;
(ii) increase adenosine level; and (iii) augment the GABAergic
effects by GABAA receptors (Yudkoff et al., 2007; Engin and
Treit, 2008; Masino et al., 2012; Lutas and Yellen, 2013). It
has been demonstrated that serotonergic, glutamatergic and
GABAergic system of different brain areas such as hippocampus
and/or amygdala have a role in the regulation of anxiety:
5-HT transporters, 5-HT receptors (e.g., 5-HT1A), N-methyl-
D-aspartate (NMDA) receptors and GABA receptors (e.g.,
GABAA receptors) are potential targets in the treatment of
anxiety disorders (Nagy et al., 1979; Kakui et al., 2009; Li,
2012; Sankar, 2012; Dias et al., 2013). It was concluded that
GABAergic system may have critical role in the modulation
of the level of anxiety: increased GABAergic transmission may
evoke anxiolytic effect (Engin and Treit, 2008; Li, 2012). Thus,
augmentation of the GABAergic effects by means of KD via
GABAA receptors may evoke a decrease in anxiety level. It has
also been demonstrated that: (i) KD may increase extracellular
adenosine level (Masino et al., 2012; Lutas and Yellen, 2013);
(ii) inhibition of adenosine receptors (A1R and A2AR) by
means of caffeine promotes anxious behavior (Klein et al.,
1991); (iii) A1R- or A2AR-knockout mice showed anxiogenic-like
behaviors (Ledent et al., 1997; Johansson et al., 2001); and
(iv) modulation of adenosine receptor activity might be an
effective treatment strategy for patients with anxiety disorders
(Kovács and Dobolyi, 2013). In addition, as KD may evoke
decreased extracellular glutamate level (Lutas and Yellen, 2013)
and NMDA receptor antagonists may have anxiolytic effects
(Guimarães et al., 1991; Engin and Treit, 2008) KD may
exert its alleviating effect on anxiety level via glutamatergic
system. Thus, theoretically, as ketone supplementation may
generate similar changes in brain neurotransmitter systems
as KD by means of ketosis (Figures 1–3), chronic and
sub-chronic ketone supplementation-provoked anxiolytic effects
may be evoked by means of glutamatergic and/or GABAergic
as well as adenosinergic system in SPD and WAG/Rij rats.
Indeed, a recent study supports the effect of ketone esters
increasing the brain GABA/Glutamate ratio in an animal model
of Angelman’s syndrome (Ciarlone et al., 2016). However,
our knowledge is not sufficient at present to explain the
mechanism(s), by which ketone supplementation exerts its
anti-anxiety effects.
We measured higher βHB levels after sub-chronic ketone
supplementation in WAG/Rij rats (KE and KSMCT) compared
to SPD rats (Figure 4A). This result and the reduced activity
of GABAergic system in WAG/Rij rat brain (Luhmann et al.,
1995) may explain that half doses of KE and KSMCT (∼2.5 g/kg
b.w./day) than applied in SPD rats (∼5 g/kg b.w./day) effectively
decreased the anxiety level in WAG/Rij rats. Higher basal ketone
levels (and its putative anti-anxiety effects) in WAG/Rij rats may
also cause lower basal anxiety levels compared to SPD rats (e.g.,
WAG/Rij rats spent more time in the open arms compared to
SPD rats before ketone supplements; Figures 2A, 3A).
In conclusion, based on the present study, we can conclude
that chronic and sub-chronic administration of exogenous
ketone supplementation may be an effective way to reduce
anxiety. Achieving nutritional ketosis with exogenous ketone
supplementation while maintaining a normal diet might be
an alternative to the KD, or may further augment the
therapeutic efficacy of the KD. Therefore, it is important
to understand the long-term effects of these supplements
fed chronically. These preliminary data show that chronic
and sub-chronic feeding of ketone supplements not only
elevated blood ketone levels, but also reduced anxiety-related
behavior, which can be highly beneficial for patients managing
diseases like epilepsy and AD with nutritional ketosis. Since
achieving nutritional ketosis requires strict dietary restrictions,
compliance is a major difficulty in this treatment. The
administration of exogenous ketone supplements that increase
ketone levels in the blood without dietary restrictions may
be an effective option to improve compliance. We propose
that exogenous ketone supplementation could provide an
alternative method to reduce anxiety for healthy individuals,
as well as those with disorders that are metabolically managed
with the KD. Therefore, further studies are needed to
determine the molecular basis of ketone supplementation-
induced anxiolytic changes, and how this strategy can be
implemented in human clinical trials with patients suffering
anxiety disorders.
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